Business
Aclarion Presents at LSI Europe ’25 Highlighting Nociscan Technology and Key Value Drivers
BROOMFIELD, Colo., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced its recent presentation at LSI Europe ’25 which is now available to investors and stakeholders. The full presentation is available for on-demand viewing here: Replay Link During
About this update from Aclarion, Inc.
[{"type":"image","alt":"Aclarion, Inc.","displaySize":"","headline":null,"caption":"Aclarion, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":140,"height":83,"url":"https://media.zenfs.com/en/globenewswire.com/ba6de721dd8ef6e3bce232e051476ebf"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/JqjNbxSKpdl2ksI_nXtiLg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTEyNTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/ba6de721dd8ef6e3bce232e051476ebf","width":140,"height":83}},"lazy":false},{"type":"text","content":"BROOMFIELD, Colo., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced its recent presentation at LSI Europe ’25 which is now available to investors and stakeholders.","length":417,"tagName":"p"},{"type":"text","content":"The full presentation is available for on-demand viewing here: Replay Link","length":74,"tagName":"p"},{"type":"text","content":"During the presentation, Chief Executive Officer Brent Ness shared how Aclarion’s flagship platform, Nociscan, combines MR spectroscopy with augmented intelligence to provide objective, biomarker-based insights into discogenic pain. Key highlights include:","length":256,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Groundbreaking Technology: Nociscan transforms MR spectroscopy signals into objective biomarker data, providing physicians insights to distinguish between painful and non-painful discs in the lumbar spine. This actionable information enables physicians to develop more personalized treatment plans for patients. ","length":311,"tagName":"p"}]},{"val":[{"type":"text","content":"Pivotal Clinical Evidence: The 300-patient CLARITY randomized clinical trial is designed to demonstrate that Nociscan-guided surgical decisioning can improve surgical outcomes for chronic low back pain beyond the current 54% industry success rate. Enrollment remains on track with internal interim results expected in Q2 2026.","length":326,"tagName":"p"}]},{"val":[{"type":"text","content":"Strong Financial Position: Recently strengthened balance sheet provides the capital needed to execute on commercial and clinical milesto...